Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) study on anticoagulant therapy in nonvalvular atrial fibrillation (NVAF)
- Conditions
- Ischemic stroke
- Registration Number
- JPRN-UMIN000006930
- Lead Sponsor
- ational Cerebral and Cardiovascular Center
- Brief Summary
PUBLICATIONS Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study. Int J Stroke. 2015; 10: 836-842. Three-month risk-bene t pro le of anticoagulation after stroke with atrial brillation: The SAMURAI-NVAF study. Int J Stroke 2016; 11: 565-574. Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation-SAMURAI-NVAF Study. Circ J. 2018 Jun 25;82(7):1935-1942
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1192
Not provided
1.Rheumatic mitral valve disease 2.A history of prosthetic valve replacement or mitral valve surgical repair 3.Active infective endocarditis 4.Patient, family member or legally responsible person does not have given informed consent 5.Inappropriate patient's conditions for study enrollment in the opinion of the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Ischemic stroke recurrence, systemic embolism and major hemorrhage during acute hospitalization or within the initial 30 days 2.Ischemic stroke recurrence, systemic embolism and major hemorrhage within 2 years. Vital and functional outcomes assessed by the modified Rankin Scale within observation period/modified Rakin scale at 3 months, 1 year, and 2 years after stroke
- Secondary Outcome Measures
Name Time Method 1.Ischemic event(ischemic stroke recurrence, revacularization, systemic embolism, ACS/PCI, DVT/PTE) 2.Hemorrhagic event(major hemorrhage, severe GI bleeding, transfusion) 3.Withdrawal of the anticoagulant therapy